Allen Mooney & Barnes Investment Advisors LLC Has $202,000 Stock Position in Abbott Laboratories (NYSE:ABT)

Allen Mooney & Barnes Investment Advisors LLC reduced its holdings in shares of Abbott Laboratories (NYSE:ABT) by 13.8% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,526 shares of the healthcare product maker’s stock after selling 244 shares during the period. Allen Mooney & Barnes Investment Advisors LLC’s holdings in Abbott Laboratories were worth $202,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in ABT. Three Seasons Wealth LLC acquired a new position in shares of Abbott Laboratories during the fourth quarter worth approximately $1,428,000. Voleon Capital Management LP bought a new stake in Abbott Laboratories during the fourth quarter worth $273,000. Bank Julius Baer & Co. Ltd Zurich boosted its holdings in shares of Abbott Laboratories by 5.5% in the 4th quarter. Bank Julius Baer & Co. Ltd Zurich now owns 1,095,443 shares of the healthcare product maker’s stock worth $133,691,000 after buying an additional 57,499 shares during the last quarter. Bank Pictet & Cie Europe AG grew its position in shares of Abbott Laboratories by 1.9% during the 4th quarter. Bank Pictet & Cie Europe AG now owns 152,719 shares of the healthcare product maker’s stock valued at $17,274,000 after acquiring an additional 2,774 shares during the period. Finally, DSM Capital Partners LLC grew its holdings in Abbott Laboratories by 75.6% during the fourth quarter. DSM Capital Partners LLC now owns 859,404 shares of the healthcare product maker’s stock valued at $97,207,000 after purchasing an additional 370,049 shares during the period. 75.18% of the stock is currently owned by institutional investors.

Insider Transactions at Abbott Laboratories

In other news, Director Sally E. Blount sold 2,600 shares of the stock in a transaction dated Wednesday, April 30th. The shares were sold at an average price of $129.66, for a total transaction of $337,116.00. Following the completion of the sale, the director now directly owns 34,058 shares in the company, valued at approximately $4,415,960.28. This represents a 7.09% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.46% of the company’s stock.

Abbott Laboratories Stock Up 0.6%

Shares of NYSE ABT opened at $134.88 on Thursday. The stock has a market capitalization of $234.67 billion, a P/E ratio of 17.63, a PEG ratio of 2.52 and a beta of 0.73. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.60 and a quick ratio of 1.14. Abbott Laboratories has a one year low of $99.71 and a one year high of $141.23. The firm’s 50 day simple moving average is $131.03 and its two-hundred day simple moving average is $126.12.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Wednesday, April 16th. The healthcare product maker reported $1.09 EPS for the quarter, topping analysts’ consensus estimates of $1.07 by $0.02. Abbott Laboratories had a net margin of 31.95% and a return on equity of 20.74%. The company had revenue of $10.36 billion for the quarter, compared to analysts’ expectations of $10.38 billion. As a group, analysts expect that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Analysts Set New Price Targets

ABT has been the topic of a number of analyst reports. Morgan Stanley boosted their target price on shares of Abbott Laboratories from $117.00 to $127.00 and gave the company an “equal weight” rating in a report on Thursday, April 17th. Stifel Nicolaus upped their target price on shares of Abbott Laboratories from $135.00 to $145.00 and gave the stock a “buy” rating in a report on Thursday, April 17th. Wells Fargo & Company raised their price target on shares of Abbott Laboratories from $136.00 to $147.00 and gave the company an “overweight” rating in a report on Thursday, April 17th. Bank of America upped their price target on shares of Abbott Laboratories from $133.00 to $150.00 and gave the stock a “buy” rating in a report on Monday, March 10th. Finally, Raymond James lifted their price objective on Abbott Laboratories from $132.00 to $142.00 and gave the company an “outperform” rating in a research note on Thursday, April 17th. Four research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $142.59.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.